myDiabby Healthcare Company Profile

Background

Overview: Founded in 2014, myDiabby Healthcare is a French company specializing in telemedicine solutions for diabetes management. The company offers a digital platform that facilitates remote monitoring and care for patients with Type 1, Type 2, and gestational diabetes. By enabling seamless communication between patients and healthcare providers, myDiabby aims to enhance the quality of diabetes care and improve patient outcomes.

Mission and Vision: myDiabby Healthcare is committed to revolutionizing diabetes management through innovative telemedicine solutions. Their mission is to provide healthcare professionals with efficient tools to monitor and support their patients remotely, thereby improving the overall quality of care and patient experience.

Industry Significance: As one of the leading telemedicine platforms in France, myDiabby Healthcare has played a pivotal role in advancing remote diabetes care. The platform is widely adopted by university hospitals, clinics, and primary care physicians, making it one of the most prevalent telemedicine solutions for diabetes in the country. Thousands of patients benefit from its services each month, highlighting its significant impact on the healthcare industry.

Key Strategic Focus

Core Objectives:

• Enhancing Remote Monitoring: Provide healthcare professionals with tools to monitor patients' glycemic data remotely, facilitating timely interventions.

• Improving Patient Engagement: Empower patients to actively participate in their diabetes management through user-friendly applications.

• Streamlining Healthcare Processes: Optimize the workflow for healthcare providers by integrating patient data into a centralized platform.

Areas of Specialization:

• Type 1 and Type 2 Diabetes: Comprehensive monitoring solutions tailored for patients with Type 1 and Type 2 diabetes.

• Gestational Diabetes: Specialized support for pregnant women managing gestational diabetes.

Key Technologies Utilized:

• Digital Medical Devices (DMn): Certified tools that comply with medical standards for data collection and monitoring.

• Interoperable Applications: Patient portals compatible with various devices to ensure seamless data integration.

Primary Markets Targeted:

• Healthcare Institutions: University hospitals, clinics, and primary care providers seeking efficient diabetes management solutions.

• Patients: Individuals with diabetes requiring consistent monitoring and support.

Financials and Funding

Funding History:

• Accelerator/Incubator Support: In January 2015, myDiabby Healthcare received backing from an accelerator/incubator program, aiding its initial development and growth.

• Secondary Transaction: In April 2023, the company underwent a secondary private transaction, indicating continued investor interest and confidence in its business model.

Estimated Financials:

• Annual Revenue: Approximately $4.3 million.

• Revenue per Employee: Estimated at $189,000.

Notable Investors:

• Eli Lilly and Company: In May 2021, myDiabby Healthcare entered into a strategic international agreement with Eli Lilly to integrate connected insulin pen solutions, reflecting significant industry collaboration.

Utilization of Capital:

• Product Development: Enhancing platform features and expanding service offerings.

• Market Expansion: Extending reach within France and exploring international markets.

• Regulatory Compliance: Ensuring adherence to medical standards and obtaining necessary certifications.

Pipeline Development

Key Pipeline Candidates:

• Integration with Connected Devices: Collaborations with companies like Eli Lilly to integrate insulin pen solutions into the platform.

• Expansion of Services: Developing features to support additional chronic conditions beyond diabetes.

Stages of Development:

• Clinical Validation: Ongoing studies to assess the efficacy and safety of new features.

• Regulatory Approval: Pursuing certifications for new tools and integrations.

Target Conditions:

• Diabetes Management: Continued focus on Type 1, Type 2, and gestational diabetes.

• Potential Expansion: Exploring applications for other chronic diseases.

Timelines for Milestones:

• Short-Term: Launch of integrated insulin pen solutions in collaboration with Eli Lilly.

• Mid-Term: Expansion of platform capabilities to include additional chronic conditions.

Technological Platform and Innovation

Proprietary Technologies:

• myDiabby Platform: A certified Class IIa medical device offering comprehensive telemonitoring solutions for diabetes care.

Significant Scientific Methods:

• Data Analytics: Utilization of algorithms to analyze patient data and generate actionable insights.

• Interoperability: Ensuring compatibility with various medical devices and electronic health records.

AI-Driven Capabilities:

• Predictive Analytics: Implementing machine learning models to predict patient outcomes and recommend interventions.

• Automated Alerts: Developing systems to notify healthcare providers of critical patient data changes.

Leadership Team

Key Executives:

• Anastasia Pichereau: Co-Founder & President.

• Pierre Altman: Co-Founder, Director & Managing Director.

• Etienne Haddad: Chief Operating Officer, Product Manager & Operations Manager.

• Cyril Vincler: Chief Technology Officer.

Professional Backgrounds:

• Anastasia Pichereau: Brings extensive experience in healthcare management and innovation.

• Pierre Altman: Expertise in business development and strategic planning within the health tech sector.

• Etienne Haddad: Background in product development and operations, focusing on healthcare solutions.

• Cyril Vincler: Specializes in technology development and system architecture for medical platforms.